{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:16:12Z","timestamp":1778667372055,"version":"3.51.4"},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,4,15]],"date-time":"2008-04-15T00:00:00Z","timestamp":1208217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Immunol"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Vaccine efficacy largely depends upon DC targeting and activation. The most potent TLR soluble ligands induce diffuse DC activation, which may be associated with marked pro\u2010inflammatory responses and possibly adverse effects. This raises the concern that effective vaccine adjuvants may similarly rely on widespread DC activation. Using a promising candidate vaccine against tuberculosis (fusion protein of Ag85B and 6\u2010kDa early secretory antigenic target (ESAT\u20106)) formulated in the potent IC31<jats:sup>\u00ae<\/jats:sup> adjuvant, DC targeting and activation was studied <jats:italic>in vivo<\/jats:italic>, following the fate of antigen and adjuvant in the draining lymph nodes, to define the magnitude of DC targeting\/activation required <jats:italic>in vivo<\/jats:italic> to induce protective vaccine responses. Unexpectedly, protective IFN\u2010\u03b3\u2010mediated Ag85B\u2010ESAT\u20106\/IC31<jats:sup>\u00ae<\/jats:sup> responses were associated to the activation of a minute population (less than 0.3%) of CD11c<jats:sup>+<\/jats:sup> lymph node DC, without detectable systemic pro\u2010inflammatory responses. This activated peripheral tissue\u2010derived DC population, characterized by enhanced CD80, CD86, CD40 and IL\u201012p40 expression, was only identified when focusing on adjuvant\u2010 or antigen\u2010labeled CD11c<jats:sup>+<\/jats:sup> DC, which were found to support T cell proliferation. Immunization with aluminum hydroxide adjuvant (Alum) resulted in a similar proportion of antigen\u2010associated DC but without detectable enhancement of CD80, CD86, CD40 or IL\u201012p40 expression. Thus, potent protective IFN\u2010\u03b3\u2010producing responses may be elicited by the exquisite activation of a minute number of <jats:italic>in vivo<\/jats:italic> targeted DC.<\/jats:p>","DOI":"10.1002\/eji.200737889","type":"journal-article","created":{"date-parts":[[2008,4,15]],"date-time":"2008-04-15T17:49:14Z","timestamp":1208281754000},"page":"1247-1256","source":"Crossref","is-referenced-by-count":43,"title":["Protective anti\u2010mycobacterial T cell responses through exquisite <i>in vivo<\/i> activation of vaccine\u2010targeted dendritic cells"],"prefix":"10.1002","volume":"38","author":[{"given":"Arun\u2004T.","family":"Kamath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario\u2004P.","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne\u2010Fran\u00e7oise","family":"Rochat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Else\u2004M.","family":"Agger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Lingnau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"von Gabain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul\u2010Henri","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire\u2010Anne","family":"Siegrist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,4,18]]},"reference":[{"key":"e_1_2_8_1_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051720"},{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.11.7235"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1210"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2006.10.005"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(98)00008-8"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(00)00218-1"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1001"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.20.100301.064842"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1329"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.9.5346"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02560.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2003.01705.x"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.12.032"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.5.2773-2778.2001"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.03.072"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.03.071"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.2.741"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(03)00175-4"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1996"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.03.007"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.5.1734.h81702001734_1734_1741"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.9.4910"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni1071"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00440-5"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200526193"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03402065"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni1449"},{"key":"e_1_2_8_28_2","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.4049\/jimmunol.162.3.1611","article-title":"CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming.","volume":"162","author":"Kovarik J.","year":"1999","journal-title":"J. Immunol."},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.7.3521-3528.2002"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2002.1775"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.2.767"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.3.1608-1617.2004"}],"container-title":["European Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Feji.200737889","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/eji.200737889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:16:11Z","timestamp":1697156171000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/eji.200737889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,18]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1002\/eji.200737889"],"URL":"https:\/\/doi.org\/10.1002\/eji.200737889","archive":["Portico"],"relation":{},"ISSN":["0014-2980","1521-4141"],"issn-type":[{"value":"0014-2980","type":"print"},{"value":"1521-4141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,18]]}}}